Atea Pharmaceuticals said its Phase 3 HCV trial met the primary endpoint, delivering 94% SBR versus 95% for standard care with an eight-week regimen for non-cirrhotic patients. Global trial results are targeted for early 2027, with an NDA submission in mid-2027.
AVIR · Atea Pharmaceuticals, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 39%
- Last earnings
- Nov 9, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Oct 2020 to Nov 2026
Up next
Latest documents
BEM/RZR met C-BEYOND’s primary and secondary endpoints, achieving 93.9% SVR versus 94.8% for SOF/VEL. C-FORWARD topline results are expected in the first quarter 2027, followed by a targeted FDA submission in the second quarter 2027; funding is expected into mid-2028.
Atea Pharmaceuticals reported that BEM/RZR met primary and secondary endpoints in Phase 3 C-BEYOND, secured a Hercules Capital credit facility for up to $200 million, and had $191.2 million in cash and investments, with current resources expected to fund operations into mid-2028.
Atea Pharmaceuticals entered a Hercules Capital senior secured term loan facility of up to $200.0 million on November 6, 2026, with $65.0 million drawn and $35.0 million conditioned on successful Phase 3 completion for BEM/RZR.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Nov 9, 2026TL;DR. C-BEYOND met its primary endpoint, C-FORWARD is fully enrolled, AT-587 advanced, and current resources are expected to fund planned operations into mid-2028. Cash and investments declined, interest income fell, and the HCV elimination bill is expected not to proceed without being reintroduced.
- + BEM/RZR met the C-BEYOND primary endpoint with a 93.91% SVR rate versus 94.75% for SOF/VEL.
- + C-FORWARD is fully enrolled with more than 880 patients across 17 countries, with topline results expected in early 2027.
- + Atea drew down $65 million from its credit facility and expects current resources to fund operations into mid-2028.
- + AT-587 completed the single-ascending-dose portion and is progressing through multiple-ascending-dose testing.
- + BEM/RZR co-administration with methadone or Suboxone was generally well tolerated and showed no drug-drug interactions.
- + The credit facility is non-dilutive and strengthens Atea’s financial position.
- − Cash and investments declined to $191.2 million at September 30, 2026 from $301.8 million at December 31, 2025.
- − Interest income and other, net declined by $1.8 million year over year because of lower investment balances.
- − Management expects the pending HCV elimination bill not to proceed and would need to be reintroduced.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| HCV external costs | 17.4M | the three months ended September 30, 2026 filing | — |
| Hercules credit facility drawdown at closing | $65M | November 6, 2026 | — |
| HEV external costs | 2.72M | the three months ended September 30, 2026 filing | — |
| Internal research and development costs | 6.98M | the three months ended September 30, 2026 filing | — |
| SVR rate (BEM/RZR, mITT at Week 24) | 93.91% | C-BEYOND mITT analysis at Week 24 | — |
| SVR rate (SOF/VEL, mITT at Week 24) | 94.75% | C-BEYOND mITT analysis at Week 24 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVIR
this stock
Atea Pharmaceuticals, Inc.
|
$318.00M | +10.9% | +622.5% | — | 3.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 14
Atea Pharmaceuticals reported that BEM/RZR met primary and secondary endpoints in Phase 3 C-BEYOND, secured a Hercules Capital credit facility for up to $200 million, and had $191.2 million in cash and investments, with current resources expected to fund operations into mid-2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVIR | -7.9% | -2.0% | -7.3% | -3.7% | +10.9% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +0.7% | +7.3% | +1.9% | +5.1% | +9.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.